Human Recombinant Insulin Market
- 2026 年市場規模
- USD 36.5 Bn
- 2033 年預估規模
- USD 60.1 Bn
- 年複合成長率 CAGR
- 7.4%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Human Recombinant Insulin Market, By Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, Premixed Human Insulin), By Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Recombinant human insulin is the synthetic insulin, developed using recombinant DNA technology by growing insulin proteins within Escherichia coli. Recombinant human insulin has a faster onset of action and lower immunogenicity than other types of insulin such as pork or beef insulin. Human insulin is available primarily in two forms: a short acting (regular) form and an intermediate acting (NPH) form. Moreover, the premixed human insulin is formed by combining two types of insulin, among which one is controls blood sugar level throughout the day, while second type of insulin helps to control blood sugar at meal times. Human recombinant insulin market is gaining traction due to development of biosimilars analogue of insulin, worldwide.
Market Dynamics
Sedentary and unhealthy lifestyle, unhealthy eating, obesity, impaired glucose tolerance, diabetes family history, and increased insulin resistance are some of the risk factors for developing diabetes among the global population. Moreover, increasing number of diabetic population, and growing research and development (R&D) studies in human recombinant insulin to introduce improved version of insulin in the market is expected to boost the growth of human recombinant insulin market in near future. Key manufactures are launching innovative and improved human recombinant insulin in the market to fulfill the increasing demand for insulin. For instance, on November 16, 2021, Viatris Inc., a pharmaceutical company and Biocon Biologics Ltd., a biopharmaceutical company announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilars products are available in vial and prefilled pen.
Key features of the study
• This report provides an in-depth analysis of the global human recombinant insulin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human recombinant insulin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd., and Dongbao Enterprise Group Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global human recombinant insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human recombinant insulin market
Market Segmentation
• Product Type Insights (Revenue, USD Bn, 2026 - 2033)
o Rapid-Acting Human Insulin
o Short-Acting Human Insulin
o Intermediate-Acting Human Insulin
o Long-Acting Human Insulin
o Premixed Human Insulin
• Brand Insights (Revenue, USD Bn, 2026 - 2033)
o Humalog
o Novolog
o Apidra
o Humulin R
o Novolin R
o Humulin N
o Novolin N
o Levemir
o Lantus
o Humalog Mix
o Novolog Mix
o Others
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
North Africa
Central Africa
South Africa
• Key Players Insights
o Novo Nordisk A/S
o Eli Lilly and Company
o Sanofi S.A.
o Julphar Gulf Pharmaceutical Industries
o Biocon Limited
o Bioton S.A.
o Gan & Lee Pharmaceuticals, Ltd.
o Zhuhai United Laboratories Co., Ltd.
o Wanbang Biopharmaceuticals Co., Ltd.
o Dongbao Enterprise Group Co., Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Global Human Recombinant Insulin Market, By Product Type
Global Human Recombinant Insulin Market, By Brand
Global Human Recombinant Insulin Market, By Distribution Channel
Global Human Recombinant Insulin Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Regulatory Scenario
o Key Developments
o Industry Trend
4. Global Human Recombinant Insulin Market, By Product Type, 2020-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Rapid-Acting Human Insulin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Short-Acting Human Insulin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Intermediate-Acting Human Insulin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Long-Acting Human Insulin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Premixed Human Insulin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
5. Global Human Recombinant Insulin Market, By Brand, 2020-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Humalog
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Novolog
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Apidra
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Humulin R
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Novolin R
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Humulin N
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Novolin N
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Levemir
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Lantus
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Humalog Mix
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Novolog Mix
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global Human Recombinant Insulin Market, By Distribution Channel, 2020-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global Human Recombinant Insulin Market, By Region, 2020 - 2033, Value (USD Bn)
o Introduction
Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Value (USD Bn)
Market Size and Forecast, By Product Type, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Brand, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
o South Africa
o North Africa
o Central Africa
8. Competitive Landscape
o Novo Nordisk A/S
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Sanofi S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Julphar Gulf Pharmaceutical Industries
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Biocon Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Bioton S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Gan & Lee Pharmaceuticals, Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Zhuhai United Laboratories Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Wanbang Biopharmaceuticals Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Dongbao Enterprise Group Co., Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
10. References and Research Methodology
o References
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們